3D-QSAR Design of New Bcr-Abl Inhibitors Based on Purine Scaffold and Cytotoxicity Studies on CML Cell Lines Sensitive and Resistant to Imatinib
Authors:
- David CabezasDavid Cabezas
- Thalía DelgadoTDThalía Delgado
- Guisselle SepúlvedaGSGuisselle Sepúlveda
- Petra KrňávkováPKPetra Krňávková
- Veronika VojáčkováVVVeronika Vojáčková
- Vladimír KryštofVKVladimír Kryštof
- Miroslav StrnadMSMiroslav Strnad
- Nicolás Ignacio SilvaNSNicolás Ignacio Silva
- Javier EcheverríaJavier Echeverría
- Christian Espinosa-BustosChristian Espinosa-Bustos
- Guido MelladoGMGuido Mellado
- Jiao LuoJLJiao Luo
Open Access
- 19 June 2025
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (6) , 925
Abstract
Background/Objectives: Bcr-Abl inhibitors such as imatinib have been used to treat chronic myeloid leukemia (CML). However, the efficacy of these drugs has diminished due to mutations in the kinase domain, notably the T315I mutation. Therefore, in this study, new purine derivatives were designed as Bcr-Abl inhibitors based on 3D-QSAR studies. Methods: A database of 58 purines that inhibit Bcr-Abl was used to construct 3D-QSAR models. Using chemical information from these models, a small group of new purines was designed, synthesized, and evaluated in Bcr-Abl. Viability assays were conducted on imatinib-sensitive CML cells (K562 and KCL22) and imatinib-resistant cells (KCL22-B8). In silico analyses were performed to confirm the results. Results: Seven purines were easily synthesized (7a–g). Compounds 7a and 7c demonstrated the highest inhibition activity on Bcr-Abl (IC50 = 0.13 and 0.19 μM), surpassing the potency of imatinib (IC50 = 0.33 μM). 7c exhibited the highest potency, with GI50 = 0.30 μM on K562 cells and 1.54 μM on KCL22 cells. The GI50 values obtained for non-neoplastic HEK293T cells indicated that 7c was less toxic than imatinib. Interestingly, KCL22-B8 cells (expressing Bcr-AblT315I) showed greater sensitivity to 7e and 7f than to imatinib (GI50 = 13.80 and 15.43 vs. >20 μM, respectively). In silico analyses, including docking and molecular dynamics studies of Bcr-AblT315I, were conducted to elucidate the enhanced potency of 7e and 7f. Thus, this study provides in silico models to identify novel inhibitors that target a kinase of significance in CML.Keywords
Funding Information
- Fondo Nacional de Desarrollo Científico y Tecnológico (1231199, 23-05474S, IGA_PrF_20242025_005011, LX22NPO5102)
- Grantová Agentura České Republiky (1231199, 23-05474S, IGA_PrF_20242025_005011, LX22NPO5102)
- Univerzita Palackého v Olomouci (1231199, 23-05474S, IGA_PrF_20242025_005011, LX22NPO5102)
- European Union—Next Generation EU (1231199, 23-05474S, IGA_PrF_20242025_005011, LX22NPO5102)
This publication has 49 references indexed in Scilit:
- Structure‐Guided Drug Design Targeting Abl Kinase: How Structure and Regulation Can Assist in Designing New DrugsChemBioChem, 2024
- Convergent synthesis, drug target prediction, and docking studies of new 2,6,9‐trisubstituted purine derivativesJournal of Heterocyclic Chemistry, 2021
- CHARMM36 all-atom additive protein force field: Validation based on comparison to NMR dataJournal of Computational Chemistry, 2013
- Best Practices for QSAR Model Development, Validation, and ExploitationMolecular Informatics, 2010
- CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fieldsJournal of Computational Chemistry, 2009
- CHARMM‐GUI: A web‐based graphical user interface for CHARMMJournal of Computational Chemistry, 2008
- On Some Aspects of Variable Selection for Partial Least Squares Regression ModelsQSAR & Combinatorial Science, 2008
- Scalable molecular dynamics with NAMDJournal of Computational Chemistry, 2005
- The Importance of Being Earnest: Validation is the Absolute Essential for Successful Application and Interpretation of QSPR ModelsQSAR & Combinatorial Science, 2003
- Validation of the general purpose tripos 5.2 force fieldJournal of Computational Chemistry, 1989